Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGE...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

robbiekuss1 Apr. 17 at 7:21 PM

$AGEN You got it Doom. 77% holy sh*t. Bot/Bal and almost 50% ownership. Time to start buying INKT Uncle Garo. We need it back in the fold.

0 · Reply

Doom_Gloom_AR Apr. 17 at 7:15 PM

$AGEN still time to buy the $INKT data https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-phase-ii-data-immune-reprogramming-and

0 · Reply

uptrend2025 Apr. 17 at 5:48 PM

$AGEN 👀 Cancer Presentation this weekend.

0 · Reply

manny11419 Apr. 17 at 4:29 PM

$AGEN According to Robin Taylor, the company is basically charging full price for orders coming from France's CCA program. I have noted that, margin seems very high for the combo base on their income statement. Recap: $4,238,000 Revenues....Cost of that Revenue:$1,022,000. Garo said they don't want to disclose selling price...1st Q report will be aggregation. However Goldberg mentioned in December that they got 60 inquires...and end of 1st quarter, that jump to 260. So basically AA, or conditional approval will open the market exponentially price will be the same, but if we are getting commercial type pricing...I'd say we are a commercial company.

1 · Reply

Spartrap Apr. 17 at 3:01 PM

$INKT AACR this weekend, with news in Gastric Cancer, 2 years worth of data, n=37, solid mechanistic rationale, very interesting study in combo with $AGEN drugs. https://clinicaltrials.gov/study/NCT06251973?term=Agent-797&viewType=Card&rank=4

2 · Reply

Biotechguy21 Apr. 17 at 2:27 PM

$AGEN this pos is so predictable 🤡🤡💰💰💩💩😂😂

0 · Reply

neversurrender2024 Apr. 17 at 2:17 PM

$AGEN come to papa and fill that gap at $4.15

0 · Reply

neversurrender2024 Apr. 17 at 2:15 PM

$AGEN fell below the 200 and 50 day...the golden cross tarnished one again!

0 · Reply

neversurrender2024 Apr. 17 at 1:35 PM

$AGEN todays garos buy day.....look for shares to go lower so he can get a better bang for his buck....lol!

0 · Reply

Gbtx1212 Apr. 17 at 12:39 PM

$AGEN I am excited that they are trying to start a P3 in neoadjuvant CRC. Obviously, they will have to figure out how to pay for this trial. Hopefully they have a good relationship with the Canadian group and can go through same process with them for neo. I hope we get updates on French revenue and P3 enrollment soon. I still feel like the odds of 4th line approval are good. In my mind, the biggest risk is competition from other 2nd gen anti-CTLA-4’s. The main one I am watching is ADG-126 (muzastotug), which is a masked anti-CTLA-4 that is in P1/2 trials. They have promising data but not nearly as much data as we have. They are a Chinese company, so I hope that hurts them in the FDA’s mind. However, they are aligned with Merck (trialed with Keytruda), which could give them a boost. They have fast track (like we do) in MSS-CRC. Hopefully we get approval first. I may buy some adagene to hedge my bets, but I still think Bot has the best chance of approval.

2 · Reply

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Apr 1, 2026, 7:30 AM EDT - 16 days ago

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Mar 26, 2026, 4:52 PM EDT - 21 days ago

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Mar 17, 2026, 4:40 PM EDT - 4 weeks ago

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Mar 16, 2026, 7:30 AM EDT - 4 weeks ago

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Mar 10, 2026, 7:30 AM EDT - 5 weeks ago

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Mar 4, 2026, 4:30 PM EST - 6 weeks ago

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Feb 19, 2026, 3:15 PM EST - 2 months ago

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Feb 9, 2026, 1:00 PM EST - 2 months ago

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Jan 21, 2026, 7:30 AM EST - 3 months ago

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Jan 20, 2026, 6:24 PM EST - 3 months ago

Agenus to Host First 2026 Stakeholder Webcast

Jan 15, 2026, 8:30 AM EST - 3 months ago

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Jan 15, 2026, 7:01 AM EST - 3 months ago

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Jan 12, 2026, 7:30 AM EST - 3 months ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

$Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC$

Dec 23, 2025, 8:05 AM EST - 4 months ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Nov 19, 2025, 4:01 PM EST - 5 months ago

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Nov 18, 2025, 8:41 AM EST - 5 months ago

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Nov 10, 2025, 7:30 AM EST - 5 months ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 5, 2025, 1:47 PM EST - 5 months ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

$Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025$

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 16, 2025, 7:48 AM EDT - 6 months ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

$France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer$

Sep 9, 2025, 7:43 AM EDT - 7 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 5, 2025, 8:52 AM EDT - 8 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 9:37 AM EDT - 8 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 19, 2025, 7:30 AM EDT - 8 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 11, 2025, 7:30 AM EDT - 8 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

$Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025$

Jul 25, 2025, 12:46 PM EDT - 9 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

$Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3$

Jul 7, 2025, 8:55 AM EDT - 10 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jun 17, 2025, 7:30 AM EDT - 10 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 11 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 11 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 11 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 11 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 15, 2025, 10:40 AM EDT - 1 year ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 7:30 AM EDT - 1 year ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 1 year ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 1 year ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 1 year ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 1 year ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 1 year ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 1 year ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 1 year ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 1 year ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 1 year ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 1 year ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

robbiekuss1 Apr. 17 at 7:21 PM

$AGEN You got it Doom. 77% holy sh*t. Bot/Bal and almost 50% ownership. Time to start buying INKT Uncle Garo. We need it back in the fold.

0 · Reply

Doom_Gloom_AR Apr. 17 at 7:15 PM

$AGEN still time to buy the $INKT data https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-phase-ii-data-immune-reprogramming-and

0 · Reply

uptrend2025 Apr. 17 at 5:48 PM

$AGEN 👀 Cancer Presentation this weekend.

0 · Reply

manny11419 Apr. 17 at 4:29 PM

1 · Reply

Spartrap Apr. 17 at 3:01 PM

2 · Reply

Biotechguy21 Apr. 17 at 2:27 PM

$AGEN this pos is so predictable 🤡🤡💰💰💩💩😂😂

0 · Reply

neversurrender2024 Apr. 17 at 2:17 PM

$AGEN come to papa and fill that gap at $4.15

0 · Reply

neversurrender2024 Apr. 17 at 2:15 PM

$AGEN fell below the 200 and 50 day...the golden cross tarnished one again!

0 · Reply

neversurrender2024 Apr. 17 at 1:35 PM

$AGEN todays garos buy day.....look for shares to go lower so he can get a better bang for his buck....lol!

0 · Reply

Gbtx1212 Apr. 17 at 12:39 PM

2 · Reply

BlackW1d0w Apr. 17 at 2:08 AM

$SPY Pro life tip - have a spoonful of raw honey or Manuka honey everyday . It will manage your sugar cravings and strengthen your immune system $AGEN

0 · Reply

Biotechguy21 Apr. 16 at 10:38 PM

$AGEN well well what do we have here? more dilution for this pos stock?????

0 · Reply

neversurrender2024 Apr. 16 at 9:54 PM

$AGEN tomorrows going to be worse..options expire and look for the big guys to kill the $ 4 's

0 · Reply

Doom_Gloom_AR Apr. 16 at 5:23 PM

$AGEN No Sir - We will be used WITH the HORSE PASTE! lol https://clinicaltrials.gov/study/NCT05318469?intr=Ivermectin&viewType=Card&locStr=California&country=US&state=California&rank=3

0 · Reply

Astrid00 Apr. 16 at 4:15 PM

$AGEN $IBRX $INKT

0 · Reply

Guptasulo Apr. 16 at 3:40 PM

$INKT $AGEN $IBRX The next wave in cancer treatment won’t be another Keytruda clone. It will be therapies that work where Keytruda fails — in cold, refractory tumors. MiNK Therapeutics + Agenus + ImmunityBio This is immune system reprogramming, not just checkpoint blocking. That’s where the real disruption begins with groundbreaking treatments.

1 · Reply

joechuck71 Apr. 16 at 3:40 PM

$AGEN View Jakub Startek’s profile Jakub Startek • 3rd+ CEO @ Grafit💎 | Design & Webflow Partner for Startups | SaaS Advisor | Webflow Enterprise Partner → grafit.agency. Visit my website 1d • Following Q1 was the kind of quarter where you're too busy to appreciate what's happening. Now that it's over, I'm looking back and thinking - wait, we actually did all of that? 🤯 In the last three months: → 4 big client projects launched: Agenus, getviktor.com, EigenPal, Flobotics → 2 Product Hunt launches: Viktor and YNS → GRAFIT's own new website went live with 4 new case studies, a new clients page, a funding page, and ABM landing pages → 32 high-quality inbound opportunities - that's almost 2x compared to last year → 2 new team members onboarded, 4 positions still open

0 · Reply

Biotechguy21 Apr. 16 at 3:33 PM

$AGEN always tomorrow….always Monday….but why is ALWAYS going on is dilution of SHs. Failure by team 24/7!

0 · Reply

BlackW1d0w Apr. 16 at 3:17 PM

$AGEN criminal that there is not a huge partnership yet.. maybe monday 😇

0 · Reply

Biotechguy21 Apr. 16 at 2:59 PM

$AGEN this pos will never go to the moon as some of you like to say. same ceo = same pos stock. Same for $INKT

1 · Reply

neversurrender2024 Apr. 16 at 2:46 PM

$AGEN big pharma can only supress the horse paste for so long..ivermectin gains ground in cancer research....garo will eventually lose the race....

0 · Reply

neversurrender2024 Apr. 16 at 2:06 PM

$AGEN garo stiffs vendors, garo stiffs his investors who is he going to stiff next.... stay tuned...

0 · Reply

Market Cap	185.46M
Revenue (ttm)	114.20M
Net Income (ttm)	120,000.00
EPS (ttm)	N/A
PE Ratio	10.04
Forward PE	3.63
Profit Margin	0.11%
Debt to Equity Ratio	-0.16

Volume	586,727
Avg Vol	665,888
Day's Range	N/A - N/A
Shares Out	38.40M
Stochastic %K	75%
Beta	1.60
Analysts	Strong Sell
Price Target	$12.33